Pharmacokinetic analysis of a combined chemoendocrine treatment with paclitaxel and toremifene for metastatic breast cancer

Breast Cancer

Volumn 16, Issue 2, 2009, Pages 113-120

  Saeki, Toshiaki ^a   Okita, Atsushi ^b   Aogi, Kenjiro ^c   Kakishita, Tomokazu ^d   Okita, Riki ^e   Taira, Naruto ^d   Ohama, Yumi ^c   Takashima, Shigemitsu ^c   Nishikawa, Kiyohiro ^f  

^a SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

^b Unnan Municipal General Hospital   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^d OKAYAMA UNIVERSITY   (Japan)

^e HIROSHIMA UNIVERSITY   (Japan)

^f NIPPON KAYAKU CO LTD   (Japan)

Author keywords

Antiestrogens; Breast cancer; Chemoendocrine therapy; Drug resistance; Paclitaxel; Toremifene

Indexed keywords

PACLITAXEL; TOREMIFENE;

ADULT; AGED; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; DRUG EFFICACY; DRUG SAFETY; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; HAIR LOSS; HEMATURIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; IN VIVO STUDY; LEUKOPENIA; MONOTHERAPY; MUSCLE WEAKNESS; MYALGIA; NAUSEA AND VOMITING; NEUROPATHY; PRIORITY JOURNAL; PROTEINURIA; STOMATITIS; TASTE DISORDER; VAGINA BLEEDING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; BONE NEOPLASMS; BREAST NEOPLASMS; DRUG TOXICITY; FEMALE; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; PROGNOSIS; SURVIVAL RATE; TISSUE DISTRIBUTION; TOREMIFENE; TREATMENT OUTCOME;

EID: 65249090187     PISSN: 13406868     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12282-008-0075-7     Document Type: Article

References (45)

1. M Dean A Rzhetsky R Allikmets 2001 The human ATP-binding cassette (ABC) transporter superfamily Genome Res 11 1156 66
2. HA Cocker N Tiffin K Pritchard-Jones 2001 In vitro prevention of the emergence of multidrug resistance in a pediatric rhabdomyosarcoma cell line Clin Cancer Res 7 3193 8
3. MM Gottesman T Fojo SE Bates 2002 Multidrug resistance in cancer: role of ATP-dependent transporters Nat Rev Cancer 2 48 58
4. BJ Trock F Leonessa R Clarke 1997 Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance J Natl Cancer Inst 89 917 31
5. T Tsuruo 1998 Mechanism of multidrug resistance and implications for therapy Jpn J Cancer Res 79 285 8
6. GD Leonard T Fojo SE Bates 2003 The role of ABC transporters in clinical practice Oncologist 8 411 24
7. JS Lagas ML Vlamning OV Tellingen 2006 Multidrug resistance protein 2 is an important determinant of PXL pharmacokinetics Clin Cancer Res 12 20 6125 32
8. B Hoogstraten SL George B Samal 1976 Combination chemotherapy and adriamycin in patients with advanced breast cancer. a Southwest Oncology Group Study Cancer 38 13 20
9. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet. 1998;352:930-42.
10. B Fisher C Redmond S Legault-Poisson 1990 Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16 J Clin Oncol 8 1005 18
11. B Fisher J Dignam N Wolmark 1997 Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer J Natl Cancer Inst 89 1673 82
12. Henderson IC, Harris JR. Breast disease. In: Henderson IC, Harris JR, editors. Principles in the management of metastatic disease, 2nd edn. New York: Lippincott; 1990. p. 547-677.
13. FJ Esteva V Valero L Pusztai 2001 Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond Oncologist 6 133 46
14. S Pyrhonen R Valavaara H Modig 1997 Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double blind, the "Nordic" phase III study Br J Cancer 76 270 7
15. IC Henderson DA Berry GD Demetri 2003 Improved outcomes from adding PXL but not from escalating doxorubicin in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer J Clin Oncol 15 976 83
16. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet. 1998;351:1451-67.
17. CK Osborne 1998 Tamoxifen in the treatment of breast cancer N Engl J Med 339 1609 18
18. A Goldhirsch JH Glick RD Gelber 2005 Meeting highlights: international consensus panel on the treatment of primary breast Cancer Ann Oncol 16 10 1569 83
19. S Chevillard P Pouillart C Beldjord 1996 Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy Cancer 77 292 300
20. M Colleoni S Li RD Gelber 2005 Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor Ann Oncol 16 5 716 25
21. M Naito K Yusa T Tsuruo 1989 Steroid hormones inhibit binding of Vinca alkaloid to multidrug resistance related P-glycoprotein Biochem Biophys Res Commun 158 1066 71
22. F Leonessa R Clark 2003 ATP binding cassette transporters and drug resistance in breast cancer Endocr Relat Cancer 10 43 73
23. R Clarke S Currier O Kaplan 1992 Effect of P-glycoprotein expression on sensitivity to hormones in MCF-7 human breast cancer cells J Natl Cancer Inst 84 19 1458 60
24. S Maruyama S Kuroiwa A Saimoto 2003 Combined effects of toremifene and paclitaxel on human breast cancer cell lines Jpn J Cancer 30 669 75
25. S Kuroiwa S Maruyama M Okada 1998 The in vitro combination-effect of toremifene with CAF on growth of various human mammary carcinomas Jpn J Cancer Chemother 25 1581 9
26. S Childs RL Yeh D Hui 1998 Taxol resistance mediated by transfection of liver-specific sister gene of P-glycoprotein Cancer Res 58 4160 7
27. E Mechetner A Kyshtoobayeva S Zonis 1998 Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin Clin Cancer Res 4 389 98
28. DM Bradshaw RJ Arceci 1998 Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance J Clin Oncol 16 3674 90
29. BI Sikic GA Fisher BL Lum 1997 Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein Can Chemother Pharmacol 40 Suppl S13 9
30. A Sparreboom O van Tellingen WJ Nooijen 1996 Tissue distribution, metabolism, and excretion of PXL in mice Anticancer Drugs 7 78 86
31. K Sai Y Saito H Fukushima-Uesaka 2008 Impact of CYP3A4 haplotypes on irinotecan pharmacokinetics in Japanese cancer patients Can Chemother Pharmacol 62 3 529 37
32. Berthou F, Dreano Y, Belloc C, Kangas L, et al. Involvement of cytochrome P450 3A enzyme family in the major metabolic pathways of toremifene in human liver microsomes. Biochem Pharmacol. 1994;47(10):1883-95.
33. V Sandor T Fojo SE Bates 1998 Future perspectives for the development of P-glycoprotein modulators Drug Resist Updat 1 3 190 200
34. SV Ambudkar S Dey CA Hrycyna 1999 Biochemical, cellular, and pharmacological aspects of the multidrug transporter Annu Rev Pharmacol Toxicol 39 361 98
35. K Michalak AB Hendrich O Wesolowska 2001 Compounds that modulate multidrug resistance in cancer cells Cell Biol Mol Lett 6 362 6
36. R Krishna LD Mayer 2000 Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs Eur J Pharm Sci 11 265 83
37. SP Cole KE Sparks K Fraser 1994 Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells Cancer Res 54 5902 10
38. T Saeki T Nomizu M Toi 2007 Dofequider fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer J Clin Oncol 25 411 7
39. T Tominaga K Hayashi A Hayasaka 1992 Phase I study of NK6222 (toremifene citrate) Jpn J Cancer Chemother 19 14 2363 72
40. JC Keen EP Miller C Bellamy 1994 P-glycoprotein and resistance to tamoxifen Lancet 343 1047 8
41. GA Fisher BL Lum J Hausdorff 1996 Pharmacological considerations in the modulation of multidrug resistance Eur J Cancer 32A 1082 8
42. Sonnichsen DS, Relling MV. Paclitaxel and docetaxel. In: Grochow LB, Ames MM, editors. A clinician's guide to chemotherapy pharmacokinetics and pharmacodynamics. Baltimore, MD: Williams & Wilkins; 1998. p. 375-94.
43. L Gianni G Capri E Munzone 1994 Paclitaxel (Taxol) efficacy in patients with advanced breast cancer resistant to anthracyclines Semin Oncol 21 Suppl 8 29 33
44. KS Albain SJ Green PM Ravdin 2002 Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from intergroup trial 0100(SWOG-8814) Proc Am Soc Clin Oncol 21 143a
45. Adachi I, Watanabe T, Abe K. Randomized comparison of sequential endocrine and chemotherapy versus combined chemo-endocrine therapy in patients with advanced breast cancer. In: Kimura K, Ota K, Yamada K, Saito H, editors. Cancer chemotherapy challenges for the future. New York: Elsevier; 1990. p. 276-87.